Cornerstone Capital Inc. Grows Position in Pfizer Inc. $PFE

Key Points

• Cornerstone Capital increased its Pfizer stake by 258.5% in the second quarter, ending with 267,909 shares valued at approximately $6.45 million. Institutional investors collectively own 68.36% of Pfizer.
• Pfizer reported quarterly EPS of $0.77, beating analyst expectations of $0.68, while revenue rose 2.6% year over year to $15.03 billion. The company maintained 2026 EPS guidance of $2.80–$3.00.
• Pfizer declared a quarterly dividend of $0.43, equivalent to $1.72 annually and a 6.4% yield. Despite mixed analyst actions, the stock carries a consensus “Hold” rating with a $28.28 price target.

Cornerstone Capital Inc. grew its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 258.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 267,909 shares of the biopharmaceutical company's stock after acquiring an additional 193,179 shares during the quarter. Cornerstone Capital Inc.'s holdings in Pfizer were worth $6,451,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Handelsbanken Fonder AB lifted its position in Pfizer by 10.4% in the 2nd quarter. Handelsbanken Fonder AB now owns 2,462,431 shares of the biopharmaceutical company's stock worth $59,295,000 after buying an additional 232,528 shares during the last quarter. Vanguard Group Inc. grew its position in Pfizer by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company's stock valued at $13,479,520,000 after acquiring an additional 7,031,162 shares during the last quarter. North Dakota State Investment Board purchased a new position in shares of Pfizer during the fourth quarter worth approximately $5,348,000. PFA Pension Forsikringsaktieselskab purchased a new position in shares of Pfizer during the fourth quarter worth approximately $76,833,000. Finally, Park National Corp OH lifted its holdings in shares of Pfizer by 332.1% in the 2nd quarter. Park National Corp OH now owns 242,081 shares of the biopharmaceutical company's stock worth $5,829,000 after acquiring an additional 186,053 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Performance

NYSE:PFE opened at $26.88 on Tuesday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. Pfizer Inc. has a fifty-two week low of $23.58 and a fifty-two week high of $28.75. The firm has a market cap of $153.21 billion, a PE ratio of 35.37 and a beta of 0.34. The business has a 50 day moving average price of $25.15 and a 200-day moving average price of $26.20.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating analysts' consensus estimates of $0.68 by $0.09. The company had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The firm's revenue was up 2.6% compared to the same quarter last year. During the same period in the prior year, the business posted $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts predict that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be given a $0.43 dividend. The ex-dividend date is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.4%. Pfizer's payout ratio is presently 226.32%.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on PFE. Wall Street Zen raised shares of Pfizer from a "hold" rating to a "buy" rating in a research note on Saturday, August 1st. Citigroup lifted their target price on shares of Pfizer from $26.00 to $27.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 29th. Weiss Ratings reissued a "hold (c)" rating on shares of Pfizer in a research note on Monday, August 3rd. Bank of America cut their price target on shares of Pfizer from $27.00 to $26.00 and set a "neutral" rating for the company in a research report on Friday, July 10th. Finally, Cantor Fitzgerald reiterated a "neutral" rating and issued a $27.00 price objective on shares of Pfizer in a report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $28.28.

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source